Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19018788 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018805 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018817 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | June 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018754 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | May 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19018773 | COMPOUNDS AS GLP-1R AGONISTS | January 2025 | May 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18434159 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) TARGETED THERAPEUTICS AND USES THEREOF | February 2024 | September 2024 | Allow | 7 | 2 | 0 | Yes | No |
| 18408663 | METHODS OF TREATING BACTERIAL INFECTIONS | January 2024 | June 2025 | Allow | 17 | 1 | 1 | No | No |
| 18175630 | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH ELEVATED ARGININE VASOPRESSIN LEVELS | February 2023 | November 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18172875 | TRIENTINE TETRAHYDROCHLORIDE AND A METHOD OF PREPARATION AND A PHARMACEUTICAL COMPOSITION THEREOF | February 2023 | February 2025 | Allow | 23 | 3 | 0 | Yes | No |
| 18151265 | COMPOSITION COMPRISING NAPHTHOQUINONE-BASED COMPOUND AS ACTIVE INGREDIENT, FOR PREVENTING OR AMELIORATING FATIGUE, CACHEXIA, PAIN, COGNITIVE DECLINE AND HEMATOPOIETIC STEM CELL REDUCTION WHICH ARE SIDE EFFECTS RELATED TO ANTICANCER DRUG TREATMENT | January 2023 | March 2025 | Allow | 27 | 3 | 0 | No | No |
| 18079904 | ALDOSTERONE SYNTHASE INHIBITORS FOR TREATING CHRONIC KIDNEY DISEASE | December 2022 | September 2024 | Allow | 21 | 2 | 0 | No | No |
| 18061127 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | December 2022 | April 2024 | Allow | 17 | 1 | 1 | No | No |
| 18007840 | PYRIDINYL MORPHOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | December 2022 | June 2025 | Allow | 31 | 0 | 0 | No | No |
| 17984405 | PHARMACEUTICAL COMPOSITIONS OF SPIRONOLACTONE FOR DEEP DERMAL DRUG DELIVERY | November 2022 | July 2025 | Allow | 32 | 4 | 0 | Yes | No |
| 18049547 | PIPERIDINYLPYRAZINE-CARBOXAMIDE COMPOUNDS FOR TREATING AND PREVENTING CANCER AND FOR DEGRADING BTK | October 2022 | March 2025 | Allow | 29 | 4 | 0 | No | No |
| 17954047 | COMPOUNDS AS GLP-1R AGONISTS | September 2022 | December 2024 | Abandon | 26 | 2 | 1 | No | No |
| 17912842 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | September 2022 | April 2025 | Abandon | 31 | 0 | 0 | No | No |
| 17929003 | PHYSICS-DRIVEN DISCOVERY OF NOVEL SMALL THERAPEUTIC COMPOUNDS FOR USE AS A BCL-2 INHIBITOR | August 2022 | June 2025 | Allow | 34 | 1 | 0 | No | No |
| 17929007 | PHYSICS-DRIVEN DISCOVERY OF NOVEL SMALL THERAPEUTIC COMPOUNDS FOR USE AS A BCL-2 INHIBITOR | August 2022 | April 2025 | Allow | 32 | 1 | 0 | No | No |
| 17792792 | IRAK4 INHIBITOR CRYSTAL AND PREPARATION METHOD THEREFOR | July 2022 | April 2025 | Allow | 33 | 1 | 0 | No | No |
| 17810620 | TREATMENT OF ANEURYSMS | July 2022 | March 2025 | Allow | 32 | 3 | 1 | No | No |
| 17848554 | COMPOSITION FOR TREATING OR PREVENTING CLIMACTERIC DISORDERS | June 2022 | October 2024 | Abandon | 28 | 2 | 0 | No | No |
| 17739506 | COMBINATION THERAPIES COMPRISING APREMILAST AND TYK2 INHIBITORS | May 2022 | October 2024 | Abandon | 29 | 2 | 0 | No | No |
| 17773098 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | April 2022 | March 2025 | Allow | 35 | 0 | 0 | No | No |
| 17641485 | CLASS OF FUNCTIONAL MOLECULES TARGETING PROTEOLYSIS PATHWAYS, PREPARATION AND APPLICATION THEREOF | March 2022 | February 2025 | Allow | 36 | 0 | 0 | No | No |
| 17631765 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITOR AND USES THEREOF | January 2022 | April 2025 | Allow | 38 | 0 | 1 | No | No |
| 17595745 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES COMPRISING NAPHTHOQUINONE DERIVATIVE | November 2021 | March 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17531216 | STABLE ANTIEMETIC EMULSIONS | November 2021 | September 2024 | Allow | 34 | 2 | 0 | No | No |
| 17611974 | Homodimeric Tobramycin Adjuvant Repurposes Novobiocin as an Effective Antibacterial Agent Against Gram-Negative Bacteria | November 2021 | April 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17595470 | SUSTAINED RELEASE LOCAL ANESTHETIC HYDROGEL COMPOSITION | November 2021 | July 2025 | Allow | 43 | 1 | 1 | No | No |
| 17612014 | TRANSITIONING PATIENTS TREATED FOR PULMONARY ARTERIAL HYPERTENSION TO SELEXIPAG | November 2021 | June 2025 | Allow | 43 | 2 | 0 | No | No |
| 17611544 | TREATMENT OF FIBROSIS WITH IRE1 SMALL MOLECULE INHIBITORS | November 2021 | April 2025 | Allow | 41 | 1 | 0 | No | No |
| 17521195 | BRM Targeting Compounds And Associated Methods Of Use | November 2021 | June 2025 | Allow | 43 | 2 | 1 | No | No |
| 17609034 | A PHARMACEUTICAL INTERMEDIATE | November 2021 | September 2024 | Allow | 35 | 0 | 0 | No | No |
| 17607449 | SOLID FORM OF DIAMINOPYRIMIDINE COMPOUND OR HYDRATE THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | October 2021 | December 2024 | Allow | 38 | 1 | 0 | No | No |
| 17606294 | IMMUNE CHECKPOINT INHIBITOR COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE | October 2021 | April 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17605402 | USE OF COMPOUND IN PREPARATION OF DRUG FOR TREATING ATHEROSCLEROSIS | October 2021 | February 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17602408 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | October 2021 | July 2024 | Allow | 34 | 0 | 0 | No | No |
| 17602139 | ANTI-FUNGAL AGENT | October 2021 | July 2024 | Allow | 33 | 2 | 1 | No | No |
| 17602133 | CHRYSOPHAENTIN ANALOGS AND USE THEREOF | October 2021 | April 2025 | Allow | 42 | 1 | 1 | No | No |
| 17601372 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | October 2021 | April 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17594128 | COMBINED USE OF A-NOR-5alpha ANDROSTANE COMPOUND DRUG AND ANTICANCER DRUG | October 2021 | March 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17600347 | METHODS OF USING MUSCARINIC ANTAGONISTS IN THE TREATMENT OF DEPRESSION | September 2021 | May 2025 | Allow | 43 | 2 | 0 | No | No |
| 17593969 | PESTICIDALLY ACTIVE DIAZINE-AMIDE COMPOUNDS | September 2021 | December 2024 | Allow | 39 | 1 | 0 | No | No |
| 17598122 | LOW-DOSE TRIPLE COMBINATION FORMULATION | September 2021 | March 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17441153 | PHARMACEUTICAL COMPOSITION | September 2021 | May 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17478152 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | September 2021 | January 2025 | Allow | 40 | 0 | 1 | No | No |
| 17440379 | MUSCLE BUILDING AGENT | September 2021 | April 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17439012 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS PROTEIN RECEPTOR KINASE INHIBITOR | September 2021 | March 2025 | Allow | 44 | 1 | 1 | No | No |
| 17438479 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | September 2021 | January 2024 | Allow | 28 | 0 | 1 | Yes | No |
| 17435607 | PROCESS FOR PREPARING 4-AMINO-5-METHYLPYRIDONE | September 2021 | July 2024 | Allow | 35 | 0 | 0 | No | No |
| 17434353 | ANILINE-BASED WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | August 2021 | July 2025 | Allow | 46 | 2 | 0 | No | No |
| 17310735 | COMPOUNDS AND METHODS OF DEUTERATED XANOMELINE FOR TREATING NEUROLOGICAL DISORDERS | August 2021 | December 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17432842 | Pyrazolopyridine Compounds For IRE1 Inhibition | August 2021 | March 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17431852 | TREATMENT OF PITT-HOPKINS SYNDROME | August 2021 | February 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17431447 | CRYSTALLINE FORM OF 1-(1-OXO-1,2-DIHYDROISOQUINOLIN-5-YL)-5-(TRIFLUOROMETHYL)-N-(2-(TRIFLUOROMETHYL)PYRIDIN-4-YL)-1H-PYRAZOLE-4-CARBOXAMIDE MONOHYDRATE | August 2021 | December 2024 | Allow | 40 | 1 | 0 | No | No |
| 17430549 | METHODS OF TREATING EPILEPSY | August 2021 | August 2024 | Allow | 36 | 0 | 1 | No | No |
| 17430248 | PROCESSES AND COMPOUNDS | August 2021 | June 2025 | Allow | 46 | 1 | 1 | No | No |
| 17430190 | PHARMACEUTICAL COMBINATION COMPRISING TNO155 AND A KRASG12C INHIBITOR | August 2021 | February 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17444573 | CRYSTALLINE PRODUCT | August 2021 | December 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17427708 | VINYLPYRIDINE CARBOXAMIDE COMPOUND AS PD-L1 IMMUNOMODULATOR | August 2021 | September 2024 | Allow | 38 | 1 | 0 | No | No |
| 17427185 | PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR | July 2021 | August 2024 | Allow | 36 | 0 | 0 | Yes | No |
| 17427357 | CRYSTALLINE FORM OF DI-P-TOLUOYL-L-TARTRATE OF UPADACITINIB | July 2021 | July 2024 | Allow | 36 | 1 | 0 | No | No |
| 17427395 | POLYVALENT DERIVATIVES OF EMOXYPINE | July 2021 | January 2025 | Allow | 41 | 1 | 0 | No | No |
| 17390631 | Pharmaceutical Composition for Preventing Greying of Hair and Preventing or Treating Poliosis or Vitiligo | July 2021 | March 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17310347 | THE MONOHYDRATE OF ROGARATINIB HYDROCHLORIDE AND SOLID STATES THEREOF | July 2021 | January 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17382624 | METHOD TO PREVENT AND TREAT ALOPECIA BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | July 2021 | October 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17424208 | COMPOSITION FOR THE TREATMENT OR PREVENTION OF INFECTIONS AND INFLAMMATIONS | July 2021 | December 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17376311 | METHOD FOR TREATING IDIOPATHIC PULMONARY FIBROSIS | July 2021 | December 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17423432 | Antimicrobial Compounds and Methods | July 2021 | July 2025 | Allow | 48 | 1 | 1 | No | No |
| 17422512 | NLRP3 MODULATORS | July 2021 | March 2025 | Allow | 44 | 1 | 1 | No | No |
| 17422650 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | July 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17422635 | TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOF | July 2021 | December 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17421179 | HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS | July 2021 | June 2024 | Allow | 35 | 0 | 0 | No | No |
| 17421318 | N-Acetylcysteine Amide (NACA) and (2R,2R')-3,3' disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) for the Prevention and Treatment of Radiation Pneumonitis and Treatment of Pulmonary Function in Cystic Fibrosis | July 2021 | December 2024 | Allow | 41 | 2 | 0 | No | No |
| 17419554 | IMMUNOSUPPRESSIVE PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | June 2021 | February 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17418442 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | June 2021 | April 2024 | Allow | 34 | 0 | 0 | No | No |
| 17417071 | CONDENSED PYRROLES AS NOVEL BROMODOMAIN INHIBITORS | June 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17416410 | KIF18A INHIBITORS | June 2021 | April 2025 | Allow | 46 | 1 | 1 | No | No |
| 17416211 | NOVEL POLYMETHOXYFLAVONE COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF | June 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17415696 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | June 2021 | September 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17345572 | METHODS FOR TREATING BRAIN METASTASIS | June 2021 | February 2024 | Allow | 32 | 2 | 0 | No | No |
| 17312321 | NITRIC OXIDE-RELEASING ANTIBACTERIAL COMPOUNDS, FORMULATIONS, AND METHODS PERTAINING THERETO | June 2021 | March 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17312371 | Methods of Treating Inflammation | June 2021 | November 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17299890 | A1 ADENOSINE RECEPTOR AGONISTS AND METHODS OF USE THEREOF | June 2021 | March 2025 | Allow | 45 | 1 | 1 | No | No |
| 17311249 | CRYSTALLINE FORMS OF A COMPOUND FOR TREATING OR PREVENTING GOUT OR HYPERURICEMIA | June 2021 | July 2024 | Allow | 37 | 1 | 0 | No | No |
| 17299999 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUND, COMPOSITION CONTAINING THE SAME AND USE THEREOF | June 2021 | June 2024 | Allow | 37 | 0 | 1 | Yes | No |
| 17311240 | DEUTERATED ANALOGS OF ACETYL-LEUCINE | June 2021 | July 2024 | Allow | 37 | 1 | 0 | No | No |
| 17309520 | SYNTHETIC DERIVATIVES OF CHOLIC ACID 7-SULFATE AND USES THEREOF | June 2021 | April 2025 | Allow | 46 | 2 | 1 | No | No |
| 17298870 | MAP4K4 INHIBITORS | June 2021 | September 2024 | Allow | 39 | 0 | 1 | No | No |
| 17298076 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | May 2021 | May 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17334601 | REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | May 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17297439 | MITOCHONDRIAL ACTIVITY INHIBITORS TARGETING TUMORAL METABOLISM | May 2021 | March 2025 | Allow | 45 | 2 | 1 | No | No |
| 17296165 | ER PROTEIN REGULATORS AND USE THEREOF | May 2021 | July 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17295231 | DISULFONATE STILBENES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | May 2021 | October 2024 | Allow | 41 | 2 | 0 | No | No |
| 17294915 | MODULATORS OF RAR-RELATED ORPHAN RECEPTORS (RORs) | May 2021 | April 2025 | Allow | 47 | 3 | 1 | Yes | No |
| 17294226 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | May 2021 | September 2024 | Allow | 40 | 2 | 0 | No | No |
| 17293595 | COMPOSITION FOR PROMOTING HAIR GROWTH COMPRISING A GUANINE DERIVATIVE | May 2021 | May 2025 | Allow | 48 | 3 | 0 | Yes | No |
| 17293742 | A CRYSTALLINE FORM OF 3- ((L-VALYL) AMINO) -1-PROPANESULFONIC ACID | May 2021 | August 2024 | Allow | 39 | 2 | 0 | No | No |
| 17316530 | CERDULATINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES | May 2021 | March 2025 | Allow | 46 | 3 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SEITZ, ANTHONY JOSEPH.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SEITZ, ANTHONY JOSEPH works in Art Unit 1629 and has examined 127 patent applications in our dataset. With an allowance rate of 65.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner SEITZ, ANTHONY JOSEPH's allowance rate of 65.4% places them in the 18% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SEITZ, ANTHONY JOSEPH receive 1.39 office actions before reaching final disposition. This places the examiner in the 30% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by SEITZ, ANTHONY JOSEPH is 41 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +32.5% benefit to allowance rate for applications examined by SEITZ, ANTHONY JOSEPH. This interview benefit is in the 83% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 35.8% of applications are subsequently allowed. This success rate is in the 76% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 55.2% of cases where such amendments are filed. This entry rate is in the 77% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 84.2% are granted (fully or in part). This grant rate is in the 93% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.4% of allowed cases (in the 68% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.